152 results about "Substituted urea" patented technology

Disclosed is a moisture-curing type curable resin composition containing: a curable resin intramolecularly having a silicon-containing functional group; and a Lewis acid or a complex of the Lewis acid as a curing catalyst, the Lewis acid being selected from the group consisting of metal halides and boron halides, which is rapidly cured at room temperature. The silicon-containing functional group is represented by general formula: —SiX¹X²X³ or —SiR¹X¹X² (wherein, X¹, X² and X³ respectively represent a hydrolytic group and may be the same as or different from each other, and R¹ represents a substituted or unsubstituted organic group having 1 to 20 carbons). If the silicon-containing functional group is —SiR¹X¹X², the curable resin further contains intramolecularly a polar component that is one of urethane, thiourethane, urea, thiourea, substituted urea, substituted thiourea, amide, and sulfide bonds, and hydroxyl, secondary amino and tertiary amino groups. Two-part type adhesive is constitutible with separating the curable resin from the curing catalyst.

The invention relates to a novel preparation method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidyl-4-yl)urea hemitartrate (pimavanserin tartrate), particularly a pharmaceutical compound for treating Parkinson's disease, of which the structural formula is disclosed as Formula (I). The invention also relates to a novel intermediate of the preparation method.

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se,

The present invention relates to tetra-substituted urea compounds which are modulators of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), their pharmaceutical compositions, and methods of using the same.

The invention discloses a continuous process for synthesizing oxamide, which belongs to the fields of catalysis, chemical industry, environmental protection and fertilizer. Coal-based synthesis gas is used to obtain H2≥99.0V% hydrogen and industrial CO through pressure swing adsorption separation technology; N2≥99.0V% nitrogen and industrial O2 are obtained through air through cryogenic separation technology. Use H2≥99.0v% hydrogen and N2≥99.0v% nitrogen to mix according to the ratio of N2:H2=1:3, and send them to the ammonia reaction tower to produce synthetic ammonia; industrial CO gas is sent to react with RONO gas after dehydrogenation, oxygen removal, and water removal The tower catalyzes the synthesis of oxalate, and the NO in the reaction tail gas is reacted with industrial O2 and an alcohol-water solution with an alcohol content of ≥10wt% to generate RONO for recycling; the synthesized oxalate and synthetic ammonia are directly sent to the reactor to synthesize oxamide, a slow-acting nitrogen fertilizer, Substituting urea or ammonium bicarbonate for agricultural and animal husbandry production has good economic and social benefits, and is an important development direction of C1 chemical and nitrogen fertilizer industries.

The present invention has its object to provide a resin composition excellent in impact resistance, tensile properties and transparency using a plant-derived biodegradable polymer obtained by positive fixation of carbon dioxide on the earth and, moldings thereof, and, further, provide a resin composition and moldings thereof improved in processability and thermal stability. The present invention relates to a resin composition which comprises (A) an aliphatic polyester type biodegradable polymer and (B) at least one copolymer selected from the group consisting of composite rubber graft copolymers (b1) and core-shell type graft copolymers (b2); or, a resin composition which comprises (A) an aliphatic polyester type biodegradable polymer and (C) at least one compound selected from the group consisting of sorbitol compounds (c1) having a particular chemical structure and urea bond-containing substituted urea compounds (c2).

A personal care product is provided which includes an unsaturated organic material with at least one olefinic double bond susceptible to degradation into a color bearing substance, the unsaturated material being selected from C₁₀-C₅₀ terpenoids and C₁₂-C₄₈ unsaturated fatty compounds selected from the group consisting of fatty alcohols, fatty acids, fatty acid glycerides, fatty acid salts and combinations thereof, a substituted urea as a stabilization agent to prevent color body formation, and a cosmetically acceptable carrier. Particularly useful as a stabilizing agent is hydroxyethyl urea.

The coating described herein attempts to provide this solution by synthesizing alkoxysilane-terminated N-substituted urea resins, then formulating them into moisture-curable single-component (1K) topside coatings. These coatings will provide greater external stability (to UV and visible radiation), cleanability, flexibility, cure times and lower VOC content than the currently qualified silicone alkyd topside coatings that are found on Navy ships. The single-component coating can include at least an alkoxysilane-terminated N-substituted urea resin, a reactive diluent, a pigment, a filler, and a catalyst. The resin can include an amino-functional silane substituted at the N-position and a non-aromatic isocyanate.

The method for synthesizing N-phenyl-N'-pyrimidyl substituted urea derivative is characterized by that in the presence of CO it uses substituted aminopyrimidine derivative and substituted nitrobenzene compound as raw material, uses selenium dioxide as catalyst, and uses organic alkali of triethylamine as catalyst promotor and makes them implement reaction in organic solvent in a slosed high-pressure still. The substituent R1 on the nitrobenzene can be one or several kinds of electron-donating and/or electron-attacting groups or be hydrogen atoms, and the substitutent R2 on the aminopyrimidine derivative can be one or several kinds of inert groups or hydrogen atoms. The mole dose of selenium dioxide is 0.1-20% of substrate, its reaction time is 2-20 hr., reaction temp. is 50-200 deg.C, and CD reaction pressure is 1-10.0 MPa (gauge pressure).

The invention provides compounds of formula I:

useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.

The invention relates to a biodegradable resin composition containing a biodegradable resin, a plasticizer and a crystal nucleus agent, the plasticizer being a compound containing two or more ester groups in the molecule thereof, wherein at least one alcohol component constituting the ester contains an alkylene oxide having 2 to 3 carbon atoms, added in the average amount of 0.5 to 5 moles per one hydroxyl group, and the crystal nucleus agent is a mixture of the following crystal nucleus agent (1) and crystal nucleus agent (2); the crystal nucleus agent (1) being the following crystal nucleus agent (1-1) or crystal nucleus agent (1-2): crystal nucleus agent (1-1): at least one selected from compounds having a hydroxyl group and an amide group in the molecule thereof; and crystal nucleus agent (1-2): at least one selected from hydroxy fatty acid esters; crystal nucleus agent (2): at least one selected from a metal salt of phenylphosphonic acid, a metal salt of a phosphate, a metal salt of an aromatic dialkyl sulfonate, a metal salt of rosinic acids, an aromatic carboxylic acid amide, rosinic acid amide, carbohydrazides, N-substituted ureas, salts of melamine compounds and uracils.

The present invention relates to a urea derivative of the formula (1)

wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.